英科再生(688087.SH)首日上市收漲255% 淄博首富劉方毅迎資本“雙子星”
格隆匯7月9日丨英科再生今日首日上市,發行價格為21.96元/股,盤中一度漲276.46%報82.67元,最終收漲255.28%報78.02元,成交16億元,換手率76.61%,市值104億元。靠着將可再生塑料變廢為“寶”,主要營收70%靠出口的英科再生在上市公吿書提及,預計今年二季度可實現營收為8.20億-9.20億元,同比增長21.51%-36.32%。另外,英科系的英科醫療今日收漲5.5%。憑藉英科醫療去年的強勢表現,董事長劉方毅成為淄博首富,此次英科再生上市,劉方毅(英科再生董事長)迎資本“雙子星”,其身價再度水漲船高。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.